Principles of breast radiation therapy
|
|
- Randall McDowell
- 5 years ago
- Views:
Transcription
1 ANZ 1601/BIG EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital Sydney Australia
2 Effects of RT: EBCTCG 2005 RT after breast conserving surgery (BCS) in N- patients (n=6097) 16% absolute decrease in local recurrence (LR) at 5 years 5% absolute decrease in breast cancer mortality at 15 years Lancet 2005;366:
3 Effects of RT: EBCTCG 2005 RT after BCS in N+ patients (n=1214) 30% absolute decrease in LR at 5 years 7% absolute decrease in breast cancer mortality at 15 years Lancet 2005;366:
4 Effects of RT: EBCTCG 2005 RT after surgery produced 70% proportional decrease in LR Four LR avoided at 5 years one breast cancer death avoided at 15 years Lancet 2005;366:
5 Effects of RT: EBCTCG 2011 RT after BCS (n=10801; 33% N+) Four recurrences avoided at 10 years: one breast cancer death avoided at 15 years Proportional benefits of RT vary little between risk groups Lancet 2011;378:
6 Effects of radiation therapy Whole breast RT standard of care after breast conserving surgery (BCS) 70% decrease in local recurrence at 5 years 50% decrease in any first recurrence at 10 years 17% decrease in breast cancer mortality at 15 years Absolute reduction in 10-year recurrence risk <10% with RT 15-year breast cancer mortality benefit of RT = 0.1% Potential to tailor RT to recurrence risks Lancet 2005;366: Lancet 2011;378:
7 Optimising patient selection for RT after breast conserving surgery
8 Personalising RT utilisation Clinical and public health priority to tailor RT utilisation to individual recurrence risks Heterogeneous tumour biology: variations in recurrence risk Advances in multidisciplinary care: falling recurrence rates Population ageing: rising breast cancer incidence underpinning importance of research to drive cost-effective health care improvements Radiother Oncol 2009;90:14-22
9 Randomised trials of RT vs no RT N Age FU LR % RT No RT PRIME CALGB BASO II 1172 < ABCSG 8a 869 > PMH 769 > NSABP B > GBSG-V SCTBG 585 <
10 Impact of consensus guidelines St Gallen 2009 and NCCN 2014 Endocrine therapy without RT may be considered in elderly patients with small ER+ N- breast cancer Minimal impact on changing practice Lack of validated clinical-pathologic markers for precise and individualised quantification of LR risk
11 Biomarkers of local recurrence Systematic review of local-regional recurrence after breast conserving therapy by IHC-defined subtypes (n=7174) Luminal A subtype associated with lowest LR rate RR 95% CI Luminal vs triple-negative Luminal vs HER HER2+ vs triple-negative Breast Cancer Res Treat 2012;133:831-41
12 Biomarkers of local recurrence IHC analysis of archived tumour specimens of RCT of RT+Tam vs Tam (n=501) 10-year LR rates by luminal A subtype RT+Tam vs Tam = 3.3% vs 7.3% (p=0.11) 10-year LR rates by clinical low-risk (age >60, T1, G1-2) luminal A subtype RT+Tam vs Tam = 5.0% vs 1.3% (p=0.42) JCO 2015;33:
13 Biomarkers of local recurrence Luminal HER2, HER2-enriched basal-like, TN non-basal JCO 2015;33:
14 Biomarkers of local recurrence Lack of standardised IHC assessment of biomarkers Multigene expression analysis for subtype identification and distant recurrence risk assessment Rapid integration into systemic therapy practice Modest impact on local therapy decision
15 Biomarkers of local recurrence Oncotype DX Recurrence Score (RS) NSABP B14 and B20 patients with HR+ N- cancer (n=1675) JCO 2010;28:
16 Biomarkers of local recurrence EndoPredict (EP) ABCSG 8 patients with HR+ HER2- cancer (n=1324) BJC 2015;112:
17 Biomarkers of local recurrence Prosigna (PAM50) Breast Cancer Prognostic Gene Signature Assay - ABCSG8 patients with HR+ HER2- cancer (n=1308) - Risk of recurrence (ROR) score and LR risk, p< ROR 57: 10-year LR rate 1.6% - Intrinsic subtype and LR risk, p=0.022 Luminal A subtype: 10-year LR rate 1.9% Fitzal F. ASCO 2014
18 ANZ 1601/BIG EXPERT Examining Personalised Radiation Therapy Investigator-driven, randomised, non-inferiority trial of RT vs no RT after BCS and adjuvant endocrine therapy in patients with luminal A early breast cancer defined using Prosigna (PAM50) Assay Biological research to enhance prognostic precision for LR Health economic research to assess cost-effectiveness of gene expression-based, risk-adapted RT utilisation
19 Optimising radiation target volume
20 Partial breast irradiation: rationale Adjuvant whole breast RT commonly involves fractionated course over 3-6 weeks PBI limits target volume to tumour bed where most LRs are observed The limited target volume permits safe acceleration of RT delivery
21 Partial breast irradiation: current status Results from RCTs (n >16,000) currently limited PBI endorsed by scientific bodies as acceptable option in selected low-risk patients primarily based on retrospective and single-arm prospective data Practical Rad Oncol 2017;7:73-9
22 Systemic review & meta-analysis of RCTs of whole breast RT vs PBI N pt1-2 pn0 PBI technique Dodwell (59-69%) MV photons Livi MV photons Olivotto MV photons Rodriguez (cn0) MV photons Ribeiro (cn0) Electrons Polgar HDR or electrons Veronesi IORT (Electrons) Vaidya IORT (50 kv x-rays) Total Radiother Oncol 2015;114:42-9
23 Systemic review & meta-analysis of RCTs of whole breast RT vs PBI Meta-analysis of two trials (n=1407) with 5 years FU showed higher LR rate with PBI than whole breast RT (p=0.002) Overall survival: no significant difference Toxicity, cosmesis, quality of life: severe toxicity <3% Radiother Oncol 2015;114:42-9
24 IMPORT LOW (CRUK 06/03) PBI using external beam (n=2018) Age 50, invasive disease 3 cm, pn0-1, margins 2 mm Whole Reduced Partial Lancet 2017;390:
25 IMPORT LOW (CRUK 06/03) Median FU 72 months Whole (n=674) Reduced (n=673) Partial (n=669) 5-year LR 1.1% 0.2% 0.5% Non-inferiority in terms of LR of partial-breast and reduceddose RT vs whole-breast RT Equivalent or fewer late normal-tissue adverse effects Lancet 2017;390:
26 GEC-ESTRO RCT PBI using interstitial brachytherapy (n=1184) Age 40, invasive disease or DCIS 3 cm, pn0-mi, margin 2 mm Median FU 6.6 years 5-year LR rates: WBI 0.9% vs PBI 1.4% (p=0.42) No significant difference in disease free or overall survival No significant difference in G2-3 skin or SC tissue toxicity Lancet 2016;387:229-38
27 RAPID/TROG RCT PBI using external beam (n=2135) Age 40, invasive disease or DCIS 3 cm, pn0 Adverse global cosmesis N WBRT PBI P Nurses Baseline % 19% years % 29% < years % 33% <0.001 Patients Baseline % 24% years % 26% years % 32% Physicians 3 years % 35% <0.001 J Clin Oncol 2013;31:
28 Randomised trials of PBI N PBI Age T cm N G3 NSABP B D CRT Interstitial MammoSite 18 3 N0-1 Y RAPID D CRT 40 3 N0 Y SHARE D CRT 50 2 N0-N0(i+) Y IRMA D CRT >49 3 N0-N1 Y
29 PBI data: interpretation Current data support PBI use for selected patients with early breast cancer PBI modalities and dose-fractionations likely to yield comparable efficacy but different toxicity Role and therapeutic benefit of PBI uncertain - Selected patients may not derive meaningful benefit - Longer term data from randomised trials essential Current off-study application should be limited to low-risk patients defined by guidelines
30 Optimising regional nodal irradiation
31 Regional nodal irradiation after axillary dissection
32 RCTs of regional nodal irradiation (RNI) CCTG MA.20 EORTC N BCS 100% 76% N0 / N1 10% / 85% 43% / 45% Median FU 9.5 years 10.9 years RT No RNI RNI P No RNI RNI P DFS 77% 82% % 72% 0.04 Distant DFS 83% 87% % 78% 0.02 Overall survival 91% 92% % 82% 0.06 NEJM 2015;373: NEJM 2015;373:317-27
33 Disease Free Survival CCTG MA.20: exploratory analysis DFS
34 CCTG MA.20 and EORTC 22922: interpretation RNI after ALND decreased local-regional and distant recurrence rates - Local-regional and systemic effects Observed benefits of RNI modest Challenge: patient selection for RNI after ALND
35 Regional nodal irradiation after positive sentinel node biopsy
36 Conclusions EORTC AMAROS N = 4806 ct1-2 cn0 BCS (82%) or mastectomy SNB+ Axillary dissection Axillary RT Adjuvant systemic therapy in 90% of both groups Lancet Oncol 2014;15:
37 EORTC AMAROS Conclusions Median FU 6.1 years ALND Axillary RT Axillary recurrence 0.4% 1.2% Disease free survival 86.9% 82.7% Overall survival 93.3% 92.5% Higher lymphoedema rate after ALND than axillary RT Lancet Oncol 2014;15:
38 EORTC AMAROS: interpretation Benefit of axillary RT likely to be modest in patients with small volume nodal disease after SNB+ - No observation only group - Low event rate: non-inferiority test underpowered - Short FU - Morbidity of axillary RT
39 ACOSOG Z11 Conclusions N = 891 (planned 1900) ct1-2 cn0 BCS + SNB 1-2 SN+ Adjuvant breast RT (RNI not permitted) ALND No ALND JAMA 2011;305:569-75
40 Conclusions Z11 clinical-pathologic characteristics ALND (n=420) No ALND (n=436) Age, median (years) T size, median (mm) ER/PR + (%) G 1/2 (%) SLN micrometastasis (%) Non-SLN metastasis (%) Systemic therapy (%) JAMA 2011;305:569-75
41 Z11 results Conclusions Median FU 6.3 years ALND No ALND Local recurrence 3.6% 1.8% Axillary recurrence 0.5% 0.9% Disease free survival 82.2% 83.9% Overall survival 91.8% 92.5% Median FU 10 years axillary recurrence: ALND 0.5% vs no ALND 1.1% JAMA 2011;305:569-75; Association Breast Surgical Conference UK 2016
42 Z11 confounding variables Variations in RT target volumes ALND No ALND High tangents 50% 53.6% Directed RNI 16.9% 21.2% Significance unclear but patients treated without ALND may derive proportionately greater benefit from RNI, increasing likelihood of non-inferiority finding J Clin Oncol 2014;32:3600-6
43 RNI trials interpretation Conclusions Challenge to rationalise results of Z11 vs CCTG MA.20 and EORTC Which patients with SNB+ should have RNI? Patients with SNB+ but do not fit Z11 profile - Should be considered for ALND - RNI may be an alternative Individualise RNI utilisation in patients with 1-2 SLN+ - Consider breast RT only for patients who fit Z11 profile - Consider RNI in presence of high-risk features - Further research to refine patient selection for RNI
44 POSNOC Conclusions N = 1900 T 5 cm BCS or mastectomy 1-2 sentinel node macrometastases Axillary dissection or RT No axillary dissection or RT
45 Tailor RT Conclusions To determine if avoiding RNI is not inferior to RNI in patients with N1, ER+, biomarker low-risk breast cancer N = 2140 BCS or mastectomy T 5 cm 1-3 N+ Endocrine therapy RNI No RNI
46 Conclusions Remarkable progress in local-regional RT in early breast cancer Decision on RT based on residual disease burden estimated using conventional histopathology and nodal prognostic groups serve patients well but increasingly inadequate Data on new generation biomarkers for LR risk prediction promising but exploratory hence prospective evaluation Future in personalised local-regional RT: integration of residual disease burden with tumour biology and efficacy of systemic therapy in multidisciplinary setting
Partial Breast Irradiation for Breast Conserving Therapy
To Radiate or Not? Is APBI the Right Compromise Solution? Partial Breast Irradiation for Breast Conserving Therapy Julia White MD Professor, Radiation Oncology Agenda Role of radiotherapy in breast conservation
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER
ACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER KHANH NGUYEN, MD, MA DEPARTMENT OF RADIATION ONCOLOGY BAYHEALTH CANCER CENTER BREAST CANCER STATISTICS Most common
More informationPost-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)
Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Conclusions When considering PMRT, use both
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationCurrent Status of Accelerated Partial Breast Irradiation. Julia White MD Professor, Radiation Oncology
Current Status of Accelerated Partial Breast Irradiation Julia White MD Professor, Radiation Oncology I have no disclosures relative to the presented material Agenda ABPI Timeline APBI by Method Clinical
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationWhole Breast Irradiation: Class vs. Hypofractionation
Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationOVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER
OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for
More informationBreast cancer. (early and advanced) Radiotherapy
Breast cancer (early and advanced) Radiotherapy Need for RT. ESTRO-HERO estimation Tumor site RT courses 2012 Increase in number 2025 Increase in rate (%) Breast 396,891 40,524 10.2 Lung 315,197 56,558
More informationIntraoperative. Radiotherapy
Intraoperative Radiotherapy ROBERTO ORECCHIA UNIVERSITY of MILAN & EUROPEAN INSTITUTE of ONCOLOGY & CNAO FOUNDATION Breast Cancer Brescia, 30th September 2011 IORT, very selective technique to intensify
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationASTRO Refresher Course 2016 Breast Cancer
ASTRO Refresher Course 2016 Breast Cancer Jennifer R. Bellon, M.D. Dana-Farber Cancer Institute Associate Professor of Radiation Oncology Harvard Medical School I have no relevant conflicts of interest
More informationBreast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016
Breast Cancer: Management of the Axilla in 2016 Greg McKinnon MD FRCSC SON Vancouver Oct 2016 No Disclosures Principle #1 There is no point talking about surgical therapy in isolation. From a patient
More informationEvaluating the Z011 study and how local-regional therapy for early breast cancer may change
Evaluating the Z011 study and how local-regional therapy for early breast cancer may change Karen Hoffman, M.D., M.H.Sc., M.P.H. Dept of Radiation Oncology The University of Texas MD Anderson Cancer Center
More informationM D..,., M. M P.. P H., H, F. F A.. A C..S..
Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationState of the Art in 2000 State of the Art today Gazing forward
2010 Buschke Lecture: The Relationship between Local Recurrence and Survival in Breast Cancer Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationCURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!?
CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!? I have no Disclosures Wolfgang Gatzemeier Breast Unit Milan, Italy 17th ESO-ESMO- EONS Masterclass in Clinical Oncology 24-29 MARCH 2018 Optimal
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More informationHypofractionated Radiotherapy for breast cancer: Updated evidence
2 rd Bangladesh Breast Cancer Conference, Dhaka, December 2017 Hypofractionated Radiotherapy for breast cancer: Updated evidence Tabassum Wadasadawala Associate Professor of Radiation Oncology Tata Memorial
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More information03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.
radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. Division of Radiation Oncology Allegheny Health Network Cancer Institute Professor of Radiation Oncology
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More information2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights
2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights Mylin A. Torres, M.D. Director, Glenn Family Breast Center Associate Professor Department of Radiation Oncology Winship Cancer Institute
More informationProfili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI
Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo BREAST CANCER Brain Adjuvant Medical Therapies
More informationRecent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective
Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective Tokyo-West Tokushukai Hospital Department of Breast Oncology Tokyo-West Tokushukai Hospital, Tokyo, Japan Kaz Sato, MD,
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Healthcare Network Philadelphia, PA Professor
More informationThe Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein
More information16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes
ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,
More informationInvasive Breast Cancer
Invasive Breast Cancer Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationBreast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective. Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL
Breast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL Radiotherapy in Early Breast Cancer Why do we do it? Who
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationBreast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director
Breast cancer staging update Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director 1 1 Review of the AJCC 8 th edition breast cancer staging Review of genomic assays as stage modifiers
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationObjectives Intraoperative Radiation Therapy for Early Stage Breast Cancer
Objectives Intraoperative Radiation Therapy for Early Stage Breast Cancer Cristina Lopez-Peñalver, MD, FACS October 11, 2014 Disclosures I have no relevant commercial relationships to disclose. Discuss
More informationIs Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?
Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Mylin A. Torres, MD Director, Glenn Family Breast Center Louis and Rand Glenn Family Chair in Breast
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationSentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD
Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More informationNEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE
NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE Dr. Joanne Chiu Medical Oncology Queen Mary Hospital The University of Hong Kong HONG KONG SURVEY FOR NEOADJUVANT THERAPY
More informationBreast cancer: Clinical evidence. of new treatments. Aero academy Conference Innovation and Safety. Patients Come First
Breast cancer: Clinical evidence of new treatments Aero academy Conference Innovation and Safety Patients Come First January 26 & 27, 2018 Lisbon, Portugal Disclosure & Disclaimer An honorarium is provided
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Medical Center Philadelphia, PA Professor (Adjunct)
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationWhy Choose Brachytherapy and Not External Beam RT or IORT?
May 30 31, 2014 Miami Beach, FL USA Why Choose Brachytherapy and Not External Beam RT or IORT? Csaba Polgár, MD, PhD, MSc National Institute of Oncology Budapest, Hungary 1 Disclosure Csaba Polgár, MD,
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationRecent Advances in Breast Cancer Treatment
Recent Advances in Breast Cancer Treatment Pornchai O-charoenrat MD, PhD, FRCST, FICS Professor Chief, Division of Head-Neck & Breast Surgery Department of Surgery, Siriraj Hospital, THAILAND Recent Advances
More informationCase Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
More informationIntra operative Intrabeam radiation for breast cancer
Intra operative Intrabeam radiation for breast cancer Dr Gillian Campbell Radiation Oncologist May 2018 Disclaimer/Conflicts I am a radiation oncology consultant at Christchurch Hospital, Canterbury Breast
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationConservative Surgery and Radiation Stage I and II Breast Cancer
Conservative Surgery and Radiation Stage I and II Breast Cancer Variant 1: Premenopausal 41-year-old woman, 1.1-cm GII IDC, upper outer quadrant (UOQ), ER/PR ( ), HER2 ( ), primary excised with lumpectomy,
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationUpdates on management of the axilla in breast cancer the surgical point of view
Updates on management of the axilla in breast cancer the surgical point of view Edwige Bourstyn Centre des maladies du sein Hôpital Saint Louis Paris Sentinel lymph node biopsy (SLNB) is the standard of
More informationCARCINOMA DELLA MAMMELLA La scelta del trattamento adiuvante: utilità clinica dei tests genomici
CARCINOMA DELLA MAMMELLA La scelta del trattamento adiuvante: utilità clinica dei tests genomici Dott.ssa Gaia Griguolo DiSCOG-Università di Padova IOV Istituto Oncologico Veneto I.R.C.C.S. Tutor: Prof.
More informationCorporate Medical Policy
Corporate Medical Policy Breast Brachytherapy for Accelerated Partial Breast Radiotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: breast_brachytherapy_for_accelerated_partial_breast_radiotherapy
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationIORT What We ve Learned So Far
IORT What We ve Learned So Far The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation
More informationTHE SURGEON S ROLE: THE AXILLA. Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital
THE SURGEON S ROLE: THE AXILLA Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital What are the concerns with treatment to the axilla Not necessary for
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006
Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Deborah Hamolsky MS, RN : DCIS Carol Franc Buck Breast Care Center UCSF Comprehensive Cancer Center Jane
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationNational Center of Oncology - Yerevan, Armenia
- Yerevan, Armenia General Information New breast cancer cases treated per year 450 Breast multidisciplinarity team members 13 Radiologists, surgeons, pathologists, medical oncologists, radiotherapists
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationWhat is an Adequate Lumpectomy Margin in 2018?
What is an Adequate Lumpectomy Margin in 2018? Stuart J. Schnitt, M.D. Brigham and Women s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School Boston, MA None Disclosures Topics Current
More informationBy Rufus Mark, MD, Gail Lebovic, MD, Valerie Gorman, MD, Oscar Calvo, PhD. TABLE 1 EARLY STAGE BREAST CANCER RANDOMIZED TRIALS M vs.
EVOLUTION OF BREAST CONSERVATION RADIATION TREATMENT TECHNIQUES IN BREAST CANCER : FROM 6 WEEKS TO 3 WEEKS TO 1 WEEK TO 1 DAY AND FROM WHOLE BREAST TO PARTIAL BREAST By Rufus Mark, MD, Gail Lebovic, MD,
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationSurgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery
Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationEvolution of Breast Surgery
Evolution of Breast Surgery Natasha Rueth MD Surgical Oncologist Piper Breast Center and Alina Health Surgical Specialists Minneapolis, MN Definitions Radical Mastectomy: Removal of breast, chest muscles,
More informationRadiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015
Radiation Treatment for Breast Cancer Melissa James Radiation Oncologist August 2015 OUTLINE External Beam Radiation treatment. (What is Radiation, doctor?) Role of radiation. (Why am I getting radiation,
More informationALND. Dr. MJ Vrancken
ALND Dr. MJ Vrancken ALND in primary surgery se1ng Axillary lymph node dissec8on (ALND) Very nice opera8on; dorsal approach 2 ALND in primary surgery se1ng Axillary lymph node dissec8on (ALND) Very nice
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationRationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York
Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant
More informationBreast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician
Breast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician Hans Wildiers Medical oncologist, Leuven, Belgium Past chairman of the EORTC elderly task force President-elect
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationPatient Selection for APBI. C. Polgár National Institute ofoncology, Budapest, Hungary
Patient Selection for APBI C. Polgár National Institute ofoncology, Budapest, Hungary Patient-, tumour- and treatment related factors affecting decision making in patient selection for APBI Patient age
More informationRecent Update in Surgery for the Management of Breast Cancer
Recent Update in Surgery for the Management of Breast Cancer Wonshik Han, MD, PhD Professor, Department of Surgery, Seoul National University College of Medicine Chief of Breast Care Center, Seoul National
More informationNew Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital
New Technologies in Radiation Oncology Catherine Park, MD, MPH Advocate Good Shepherd Hospital Breast Radiation Early Stage Breast Cancer Whole Breast Radiation Delivered to the whole breast Boost to the
More informationAdvances in Localized Breast Cancer
Advances in Localized Breast Cancer Melissa Camp, MD, MPH and Fariba Asrari, MD June 18, 2018 Moderated by Elissa Bantug 1 Advances in Surgery for Breast Cancer Melissa Camp, MD June 18, 2018 2 Historical
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationGenomic Profiling of Tumors and Loco-Regional Recurrence
1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationAccelerated Partial Breast Irradiation
Accelerated Partial Breast Irradiation OSCO/OU Stephenson Cancer Center Saturday, March 5, 2016 Robert Kuske, MD, FAACE Founder, Medical Director Arizona Breast Cancer Specialists Scottsdale, Arizona 1
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More information